P. Sen

Phase I Study of Dovitinib (TKI258), an Oral FGFR, VEGFR, and PDGFR Inhibitor, in Advanced or Metastatic Renal Cell Carcinoma

J. Soria, M. Shi, Chia‐Chi Lin, 2013, Clinical Cancer Research.

BM-32CERITINIB (LDK378) FOR TREATMENT OF PATIENTS WITH ALK-REARRANGED (ALK+) NON-SMALL CELL LUNG CANCER (NSCLC) AND BRAIN METASTASES (BM) IN THE ASCEND-1 TRIAL

Michael Thomas, A. Shaw, Gregory Riely, 2014 .

Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma.

M. Milowsky, D. Bajorin, C. Sternberg, 2014, European journal of cancer.

First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study

Serafino Pantano, Yi-long Wu, Chun-Ming Tsai, 2017, The Lancet.

Ceritinib Efficacy and Safety in Treatment-Naive Asian Patients With Advanced ALK-Rearranged NSCLC: An ASCEND-4 Subgroup Analysis

Yi-long Wu, Chun-Ming Tsai, T. Hsia, 2020, JTO clinical and research reports.

Final results of a multicenter, open-label phase II trial of dovitinib (TKI258) in patients with advanced urothelial carcinoma with either mutated or nonmutated FGFR3.

D. Bajorin, C. Sternberg, M. Shi, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PL03.07: First-line Ceritinib Versus Chemotherapy in Patients with ALK-rearranged (ALK+) NSCLC: A Randomized, Phase 3 Study (ASCEND-4)

Yi-long Wu, L. Crinò, Chun-Ming Tsai, 2017 .

Efficacy and Safety of Ceritinib 450 mg/day with Food and 750 mg/day in Fasted State in Treatment-Naïve Patients with ALK+ Non–Small Cell Lung Cancer: Results from the ASCEND-8 Asian Subgroup Analysis

Keunchil Park, Dong-Wan Kim, B. Cho, 2022, Cancer research and treatment.

First-line ceritinib versus chemotherapy in patients (pts) with advanced ALK rearranged (ALK+) non-small cell lung cancer (NSCLC): ASCEND-4 Asian subgroup analysis

T. Hsia, F. Branle, P. Yu, 2019, Annals of Oncology.